New drug combo shows promise in early cancer trial
NCT ID NCT03530397
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This early-phase study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SELECTED ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Detroit, Michigan, 48202, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Chapel Hill, North Carolina, 27599, United States
-
Research Site
Providence, Rhode Island, 02903, United States
-
Research Site
Chattanooga, Tennessee, 37404, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Melbourne, 3004, Australia
-
Research Site
Randwick, 2031, Australia
-
Research Site
Bordeaux, 33075, France
-
Research Site
Lyon, 69373, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Meldola, 47014, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Ravenna, 48121, Italy
-
Research Site
Roma, 168, Italy
-
Research Site
Amsterdam, 1066 CX, Netherlands
-
Research Site
Lisbon, 1649-035, Portugal
-
Research Site
Porto, 4200-072, Portugal
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Gyeonggi-do, 13620, South Korea
-
Research Site
Incheon, 21565, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
A Coruña, 15006, Spain
-
Research Site
Barcelona, 08003, Spain
-
Research Site
Barcelona, 08028, Spain
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08041, Spain
-
Research Site
Barcelona, 08916, Spain
-
Research Site
Majadahonda, 28222, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Valencia, 46010, Spain
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 10048, Taiwan
Conditions
Explore the condition pages connected to this study.